Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04000334
Other study ID # CHM-2019/S3/04
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date July 29, 2020
Est. completion date September 2022

Study information

Verified date March 2022
Source Centre Hospitalier le Mans
Contact Christelle Jadeau, PD
Phone 0 (33) 2 43 43 43 43
Email cjadeau@ch-lemans.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Hypoxic-ischaemic brain injury (HIBI) is the main cause of death in patients who are comatose after resuscitation from cardiac arrest. Current guidelines recommend to target a mean arterial pressure (MAP) above 65 mmHg to achieve an adequate organ perfusion. Moreover, after cardiac arrest, cerebral autoregulation is dysregulated and cerebral blood flow (CBF) depends on the MAP. A higher blood pressure target could improve cerebral perfusion and HIBI. Transcranial Doppler (TCD) is a non-invasive method to study CBF and its variations induced by MAP. The aim of this study is to test the feasibility of an early-goal directed hemodynamic management with TCD during the first 12 hours after return of spontaneous circulation (ROSC).


Recruitment information / eligibility

Status Recruiting
Enrollment 40
Est. completion date September 2022
Est. primary completion date September 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients admitted in the Intensive Care Unit (ICU) under mechanical ventilation with a Glasgow Coma Scale = 8/15 after in- or out-of-hospital cardiac arrest - Mean arterial pressure between 65 and 85 mmHg with or without vasopressor support Exclusion Criteria: - Age < 18 years old - No flow (time between cardiac arrest and the beginning of cardiac massage) > 15 minutes or unknown - Low flow ((time between cardiac arrest and ROSC: return of spontaneous circulation)> 60 minutes - Time between ROSC and inclusion > 12 hours - Transcranial doppler unavailable - Cardiac arrythmia - Patient under extracorporeal life support before inclusion or at risk of being referred for assistance due to cardiogenic shock with high dose of vasopressors before inclusion (MAP < 65 mmHg with norepinephrine or epinephrine > 1 µg/kg/min or dobutamine > 10 µg/kg/min) - Severe cardiac dysfunction defined by left ventricular ejection fraction < 20% or aortic Velocity Time Integral (VTI: measured with trans-thoracic echocardiography) < 14 cm with dobutamine > 10µg/kg/min - Patient under Extracorporeal Membrane Oxygenation (ECMO) for Acute Respiratory Distress Syndrome (ARDS) before inclusion - Cardiac arrest secondary to brain injury such as stroke, subarachnoid hemorrhage or traumatic brain injury - Hemorrhagic shock - Any acute pathology that requires strict blood pressure control (aortic dissection, stroke, cardiogenic pulmonary edema with high blood pressure) - Decision of withdrawing or withholding life sustaining treatment before inclusion or considered during the first 12 hours of ICU management - Patient with a modified Rankin scale (MRS) 4 or 5 prior to resuscitation - Pregnancy or lactation - Patients already enrolled in another clinical study on cardiac arrest - Patients with judicial protection - No social security coverage

Study Design


Intervention

Other:
MAP increased to optimize cerebral blood flow
MAP will be increased to 90-100 mmHg with norepinephrine. If TCD is still abnormal with a MAP of 90-100 mmHg, MAP will be increased to 100-110 mmHg. At each step, all CBF determinants will be recorded as well as cardiac output and Veinous jugular oxygen saturation (SvjO2). When TCD is normalized with no complications, MAP will be maintained at 90-100 or 100-110 mmHg during 24 hours.
MAP between 65 and 85 mmHg
MAP will be maintained between 65-85 mmHg, using a norepinephrine infusion as needed.

Locations

Country Name City State
France Centre Hospitalier Le Mans Le Mans

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier le Mans

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of patients in whom the transcranial doppler goal directed therapy will result in a modification of MAP targets Proportion of patients in whom transcranial doppler goal directed therapy will result in a modification of MAP targets. In the first hour after inclusion
Secondary Cerebral blood flow modifications induced by increasing MAP Transcranial doppler data modifications induced by increasing MAP to 90-100 mmHg and 100-110 mmHg. At the 6th, 12th, 24th, 48th and 72nd hour after inclusion
Secondary Cerebral oxygenation modifications induced by increasing MAP Bulb jugular venous oxygen saturation modifications induced by increasing MAP at 90-100 mmHg and 100-110 mmHg. At the 6th, 12th, 24th, 48th and 72nd hour after inclusion
Secondary Undesirable events induced by increasing MAP Number of cardiovascular events defined by new onset of severe cardiac arrythmias, acute coronary syndromes, cardiogenic pulmonary edema, cardiogenic shock or cardiac arrest At te 24th hour after inclusion
Secondary Undesirable events induced by increasing MAP Number of neurologic events defined by intracranial hematoma or brain death At the 72nd hour after inclusion
Secondary Plasmatic concentrations of Neuron Specific Enolase Neuron Specific Enolase (NSE) plasmatic concentrations at H+72h after cardiac arrest At the 72nd hour after inclusion
Secondary 28 day survival Proportion of patients alive 28 days after inclusion 28 days after inclusion
Secondary 90 days survival Proportion of patients alive 90 days after inclusion 90 days after inclusion
Secondary Measure of the degree of disability in the activities of daily living of the included patients Modified Rankin scale (MRS) 90 days after inclusion. The scale runs from 0-6, running from perfect health without symptoms to death.
0 - No symptoms.
- No significant disability. Able to carry out all usual activities, despite some symptoms.
- Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities.
- Moderate disability. Requires some help, but able to walk unassisted.
- Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted.
- Severe disability. Requires constant nursing care and attention, bedridden, incontinent.
- Dead.
90 days after inclusion
See also
  Status Clinical Trial Phase
Recruiting NCT06048068 - Removing Surrogates' Uncertainty to Reduce Fear and Anxiety After Cardiac Events N/A
Recruiting NCT05558228 - Accuracy of Doppler Ultrasound Versus Manual Palpation of Pulse in Cardiac Arrest
Completed NCT03685383 - Cytokine Adsorption in Post-cardiac Arrest Syndrome in Patients Requiring Extracorporeal Cardiopulmonary Resuscitation N/A
Completed NCT04619498 - Effectiveness of an Interactive Cognitive Support Tablet App to Improve the Management of Pediatric Cardiac Arrest N/A
Completed NCT04584645 - A Digital Flu Intervention for People With Cardiovascular Conditions N/A
Not yet recruiting NCT05649891 - Checklists Resuscitation Emergency Department N/A
Withdrawn NCT02352350 - Lactate in Cardiac Arrest N/A
Completed NCT03024021 - Cerebral Oxymetry and Neurological Outcome in Therapeutic Hypothermia
Completed NCT02247947 - Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome
Completed NCT02275234 - Care After Resuscitation
Completed NCT01936597 - Prospective Study of 3 Phone Assistance Strategies to Achieve a Continuous Cardiac Massage N/A
Completed NCT01944605 - Intestinal Ischemia as a Stimulus for Systemic Inflammatory Response After Cardiac Arrest N/A
Completed NCT01972087 - Simulation Training to Improve 911 Dispatcher Identification of Cardiac Arrest N/A
Active, not recruiting NCT01239420 - Norwegian Cardio-Respiratory Arrest Study
Completed NCT00878644 - Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-OH [Out of Hospital] Trial Phase 3
Completed NCT00880087 - Therapeutic Hypothermia to Improve Survival After Cardiac Arrest in Pediatric Patients-THAPCA-IH [In Hospital] Trial N/A
Completed NCT01191736 - Ultra-Brief Versus Brief Hands Only CPR Video Training With and Without Psychomotor Skill Practice N/A
Completed NCT00729794 - Vasopressin, Epinephrine, and Steroids for Cardiac Arrest Phase 3
Recruiting NCT00441753 - Cerebral Bloodflow and Carbondioxide Reactivity During Mild Therapeutic Hypothermia in Patients After Cardiac Arrest N/A
Completed NCT00347477 - Fluid Shifts in Patients Treated With Therapeutic Hypothermia After Cardiac Arrest Phase 3